INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the coronavirus infection 2019 (COVID-19), has affected >200 countries with around 400 million people infected and more than six million deaths worldwide. Despite few cases progressing to severe pneumonia and around 85% of patients presenting mild symptoms or being asymptomatic,\textsuperscript{1} the prolonged use of immunosuppressants and underlying immune system dysregulation in rheumatoid arthritis (RA) patients might make this group more susceptible to COVID-19 than the general population, with a trend to higher disease severity.\textsuperscript{2-5} Several advances have been made on describing in detail how the immune system responds to COVID-19,\textsuperscript{6,7} but less is known about how this is done in RA patients.
specifically. Recent data have reported a robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 in general, yet little is known whether the subset of patients with RA is also able to develop protective COVID-19-specific T/B cell responses.

2 | MATERIAL AND METHODS

2.1 | Study design

Monozygotic twin brothers aged 47 were included in the study. Both were diagnosed with RA for >15 years following the American College of Rheumatology (ACR) criteria. At the time of this study, they both presented the same RA activity and were being both treated with methotrexate (20 mg/week) and adalimumab (40 mg every other week). The treatment was stopped in both twins after COVID-19 diagnosis in Twin+, following ACR guidance for RA management during the pandemic. Both twins were negative for rheumatoid factor (RF IgM) and anticitrullinated protein antibodies (CCP2 IgG). The participants provided written informed consent approved by the regional ethical research board.

Peripheral blood was collected and PBMCs isolated following standard guidelines. Samples were collected from both twins 3 weeks after Twin+ became fully recovered, meaning no symptoms and negative RT-PCR for COVID-19.

2.2 | COVID-19 diagnosis

RT-PCR assay was used to detect the presence of SARS-CoV-2 nucleic acid in throat swab samples using the EURORealTime SARS-CoV-2 (Euroimmun, Germany, Lübeck) kit. Serum samples were used to evaluate the titres of anti-SARS-CoV-2 IgG and IgA antibodies (Euroimmun) at Karolinska University Hospital.

2.3 | FACS

PBMCs were stained as previously described. The complete list of antibodies used can be found in the table S1. Cells were acquired in CytoFLEX cytometer (Beckman Coulter), and data analyzed with FlowJo (TreeStar).

2.4 | Functional assay

PBMCs were seeded in Human IFN-γ/IL-2 FluoroSpot Kit (Mabtech, Sweden) plates and stimulated with PepMix SARS-CoV-2 nucleoprotein (NCAP) and spike glycoprotein (SG) from JPT Peptide Technologies (Berlin, Germany) for 18h at 37°C. The SARS-CoV-2 S1 domain of spike glycoprotein (S1) and S2 domain of spike protein plus nucleoprotein (S2+N) defined peptide pool from Mabtech were also used. Phytohemagglutinin was assessed as positive control. The plate was developed and read using Mabtech Iris (Mabtech).

SARS-CoV-2-specific B cell response was assessed by using the Human IgG SARS-CoV-2 RBD FluoroSpot (Mabtech) specific to the receptor binding domain (RBD) of the S1 domain. PBMCs were firstly stimulated with R848 + IL-2 for 96h and then transferred to precoated IgG FluoroSpot plate and incubated overnight. Total IgG production was also assessed.

2.5 | Immune cell receptors next-generation sequencing

Genomic DNA was isolated from PBMCs and applied for survey-level deep sequencing of the T cell receptor β-chain (TCRB) and immunoglobulin heavy chain (IGH) employing the ImmunoSEQ platform (Adaptive Biotechnologies, Seattle, WA). For TCR γ-chain (TCRG) sequencing, γδ T cells were purified using the Anti-TCRγ/δ MicroBead Kit (Miltenyi Biotec) prior to DNA isolation. NGS data analysis was performed as previously described.

3 | RESULTS

Twin+ presented several days history of cough, loss of smell and taste and fever before having confirmed COVID-19 with RT-PCR on March 4. In the following 3 weeks, he presented flu-like symptoms and was medicated at home with analgesics and antipyretic drugs until the symptoms resolved completely on March 25. Corticosteroids were not administered. During the course of his infection, Twin+ stopped RA medication and no flares or disease worsening were noticed until medications resumed. Twin- presented persistent negative RT-PCR, but also transiently stopped medication. On April 15, both twins were sampled.

COVID-19 infection is associated with an intense dysregulation of immune responses. To assess the degree of this dysregulation in the cellular compartment, we analyzed the αβ T cell composition. Twin- and Twin+ presented no differences on CD4+ and CD8+ T cell composition of effector-memory (TEM), central-memory (TCM) and HLA-DR+CD38+ populations, PD1 nor CD28 expressions (Figure S1).
We then assessed changes on unconventional γδ T cell composition. Twin+ presented notable decrease in Vδ2+ and increase in Vδ1 Vδ2− populations (Figure 1A). Vδ2+ T cells showed a remarkable increase in TEM in Twin+, while Vδ1+ population presented an increase in both TEM/TCM populations (Figure 1B). We found a twofold increase in Vδ1+CD27low/−CD45RO− adaptive like cells,14 high NKG2D and low PD1 expressions in γδ T cells from Twin+ (Figure 1B-C).

In order to assess the COVID-19-specific T cell response, we performed a FluoroSpot assay using several COVID-19 peptides. Twin− showed no T cell responses to any of the peptides, as observed by IFNγ (Figure 1D) and IL-2 production (Figure S2). We found no signs of cross-reactivity, even against S2 peptides, a domain with high homology to other coronaviruses.15 Twin− showed high responses to NCAP, SG, S1 and some response to S2+N, confirming that he had developed persistent COVID-19-specific T cell responses (Figure 1D, Figure S2).

As for B cell composition, Twin+ presented higher memory and lower naïve B cells percentage than Twin− and an increase in IgD IgM− B cell population (Figure 1E). Twin+ also presented lower CD24hiCD38lo immature/transitional and CD24hiCD38int frequencies, but higher frequency of CD24loCD38−, CD24+CD38−, CD24hiCD27+ and CD24 CD27− low B cell populations than Twin− (Figure 1F-G). We then performed ELISpot11,12 to enumerate B cells secreting IgG antibodies specific to SARS-CoV-2 RBD domain, which present the lower homology with other coronaviruses as compared to S2.15 We observed that Twin− presented no RBD-specific B cell response, while Twin+ showed increased SFU with increasing number of cells incubated (Figure 1H) and positivity for anti-SARS-CoV-2 IgA antibodies (ratio=2.2), further confirming his infection.

Next, we evaluated the immune changes at the repertoire level of TCRB, TCRG and IGH chains. Viral infections are associated with reduced TCR/BCR diversities due to the clonal expansion of virus-specific clonotypes, resulting in skewed spectratyping. Surprisingly, we found that Twin+ presented much higher diversity for all immune cell receptors evaluated (Figure 2A) and a gaussian CDR3 spectratype distribution (Figure 2B), indicative of a healthy and diverse repertoire distribution.

Previous reports have described that identical twins present higher variable-joining (V-J) similarities than unrelated people and biased segment usage.16 Assessing the pairing of V-J gene segments in all chains, we found that Twin+ presented several changes on V-J pairing frequencies in TCRG chain, but few changes on TCRB and IGH chains (Figure 2C). Altogether, these data indicate that, despite that there is higher TCR diversity in the COVID-19+ twin, the most used V-J family usage and pairing are still very similar.

Next, we assessed the repertoire overlap between the twins and the presence of hyperexpanded clones in Twin+ as compared to Twin−. The chain with more overlapping clonotypes was TCRG (r2 = .306), followed by TCRB (r2=0.0802) and IGH, that presented just a single overlapping clonotype (r2 = 0) (Figure 2D). We then annotated the clones hyperexpanded in Twin+, which could represent the ones COVID-19-specific. We found 124 TCRB, 215 TCRG and only 1 IGH clonotype enriched in Twin+ as compared to Twin− (Table S2).

VDJdb database (https://vdjdb.cdr3.net) was searched for TCRB clonotypes specific to COVID-19 epitopes and to other common pathogens, as both twins presented positive serology for CMV. We observed that both twins presented prominent presence of cytomegalovirus-specific clonotypes and to influenza A (Figure 2E). Twin− presented considerable percentage of the Epstein–Barr virus (EBV)-specific clones but not a single TCRB clonotypes specific to COVID-19, while Twin+ presented very few clones EBV-specific and 0.001% of TCRB repertoire COVID-19-specific (Figure 2E). Table S3 presents the full description of the clones.

4 | DISCUSSION

Despite that several works have shed light into COVID-19 immune response,6,7 important questions have remained unanswered, such as how RA patients’ immune system control the infection and whether this population can develop robust COVID-19-specific adaptive cell responses. Here, we report a unique observation of immunological changes associated with COVID-19 clearance in identical twins, male and seronegative for the most used RA-associated markers.17 We found an expansion of Vδ2+ γδ T cells in Twin+, indicating that these cells might play a role on COVID-19 infection control as earlier shown for CMV.18 In fact, the increase in Vδ2+ γδ T cells was associated with clinical benefits in recovered COVID-19 patients.19 Further studies are required to confirm our findings, including a control group of non-RA patients.

A recent report have shown that seronegative exposed donors and patients with mild or asymptomatic COVID-19 developed a robust T cell response that can mediate long-term immune protection against reinfec- tion.8 RA patients present several immune aberrancies that may result in ineffective generation of a protective adaptive immune response protective to COVID-19.4,20 Additionally, the prolonged use of immunosuppressants in this population also contribute to an overall higher risk of severe infections and to a defective immune response,4 despite some reports not showing a clear association between disease severity with some rheumatic
**FIGURE 1** Twin+ presented COVID-19-specific T/B cell responses. A, V61 and V62 expression by γδ T cells. B, FACS characterization of effector-memory (TEM, CD45RO⁺CCR7⁻), central-memory (TCM, CD45RO⁺CCR7⁺), CD45RA-expressing effector-memory (TEMRA, CD45RO⁻CCR7⁻) and naïve (TN, CD45RO⁻CCR7⁺) population distribution in Vδ1+ and Vδ2+ cells. Vδ1⁺CD27lowCD45RO⁻ population is highlighted. C, NKG2D and PD1 expression (median fluorescence intensity, MFI) by Vδ1+ and Vδ2+ γδ T cells. D, T cell response to COVID-19 peptides measured by IFNγ+ spot forming units (SFU). U, untreated; PHA, phytohemagglutinin; NCAP, nucleoprotein; S1, S1 domain of the spike glycoprotein; S2, S2 domain of the spike glycoprotein. (E) CD19⁺ B cell FACS characterization of switched-memory (SM, CD27⁺IgD⁻), non-switched-memory (NSM, CD27⁺IgD⁺), double-negative (DN, CD27 IgD⁻) and naïve (N, CD27 IgD⁺) IgD⁻IgM⁻ population is highlighted.

**FIGURE 2** Twin+ displayed higher TCR/BCR diversity than Twin-. A, TCRB, TCRG and IGH diversity metrics measured as inverse Simpson's index (1/Ds). B, TCRB (left), TCRG (middle) and IGH (right) CDR3 spectratype. Bars represent frequency of unique CDR3 sequences with different amino acid (aa) lengths. C, Variable-joining segments pairing in CDR3 sequences of TCRB (upper), TCRG (middle) and IGH (bottom) chains. Chord diagram is used for visualization, ribbons connecting segment pairs are scaled by corresponding V-J pair frequency. D, TCRB, TCRG and IGH repertoire overlap. The clonotype abundance scatter plot shows the CDR3 sequences overlap between twins. The main frame contains a scatterplot of overlapping clonotypes and a linear regression. Point size is scaled to the clonotype abundance in both samples. The axes represent log10 clonotype frequencies in each sample. R² represents squared Pearson's correlation coefficient. E, Percentage of TCRB CDR3 sequences specific to cytomegalovirus (CMV), influenza A, Epstein–Barr virus (EBV) and COVID-19 (SARS-CoV-2)
Despite the stochastic nature of T cell and B cell clonotypes generation, identical twins present high similarity in TCR V-gene segment usage and increased number of identical CDR3 sequences when compared to unrelated individuals.\textsuperscript{16,24} This makes studies with twins quite valuable in autoimmune diseases and infections. Here, we report unexpected low clonotype sharing between twins, probably as a result of immune repertoire reshaping induced by COVID-19 infection. Infections trigger massive T cell expansion, leading to the skewing of the TCR repertoire due to antigen-specific T cell expansion, as observed in CMV.\textsuperscript{15} Overall, our results indicate that a remarkable reshaping of the TCR and BCR repertoires might take place after COVID-19 infection in RA. Further investigation is required to assess whether the sequences here reported are protective to COVID-19 infection,\textsuperscript{25} including longitudinal sampling and the assessment of a control group.

**ACKNOWLEDGMENTS**

The authors thank the patients enrolled in the study.

**CONFLICT OF INTEREST**

The authors have no competing interests.

**AUTHOR CONTRIBUTIONS**

LCMA and AG performed experiments, collected and analyzed the data, wrote the paper and approved the final version of the manuscript; RSR and BM provided key/unique reagents, wrote the paper and approved the final version of the manuscript. MU provided key/unique reagents, supervised the study, wrote the paper and approved the final version of the manuscript.

**ETHICS STATEMENT**

The study was performed in accordance with the Declaration of Helsinki and approved by the Regional Ethical Review Board of Stockholm, Sweden.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are openly available in immuneACCESS at https://doi.org/10.21417/LCMA2022SJJ.\textsuperscript{26}

**REFERENCES**

1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* 2020;8:420-422.
2. Zhong Jixin, Shen Guifen, Yang Huiqin, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. *Lancet Rheumatol.* 2020;2:E557-E564. doi:10.1016/S2665-9913(20)30227-7
3. Ye C, Cai S, Shen G, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. *Ann Rheum Dis.* 2020;79(8):1007-1013. doi:10.1136/annrheumdis-2020-217627
4. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. *Rheumatol. (United Kingdom).* 2013;52:53-61.
5. England BR, Roul F, Yang Y, et al. Risk of COVID-19 in rheumatoid arthritis: a national veterans affairs matched cohort study in at-risk individuals. *Arthritis Rheumatol.* 2021;73(12):2179-2188. doi:10.1002/art.41800
6. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. *J Exp Med.* 2020;1-10. doi:10.1084/jem.20200678
7. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of the Science. *Immunity.* 2020;52(6):910-941. 10.1016/j.immuni.2020.05.002
8. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell.* 2020;183(1):158-168. doi:10.1016/j.cell.2020.08.017
9. Aletaha D, Neogi T, Silman AJ. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League against rheumatism collaborative initiative (annals of the rheumatic diseases (2010) 69, (1580–1588)). *Ann Rheum Dis.* 2010;69:1892.
10. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the management of adult patients with rheumatic disease during the COVID-19 Pandemic. *Arthritis Rheumatol.* 2020;72:1241-1251. doi:10.1002/art.41301
11. Arruda LCM, Gaballa A, Uhlin M. Graft \(\gamma\delta\) TCR sequencing identifies public clonotypes associated with hematopoietic stem cell transplantation efficacy in acute myeloid leukemia patients and unwarovies in cytomegalovirus impact on repertoire distribution. *J Immunol.* 2019;202:1859-1870.
12. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan. *China. Clin. Infect. Dis.* 2020;71:762-768. doi:10.1093/cid/ciaa248
13. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020;130(5):2620-2629. doi:10.1172/JCI137244
14. Davey MS, Wilcox CR, Joyce SP, et al. Clonal selection in the human Vδ1 T cell repertoire indicates \(\gamma\delta\) TCR-dependent adaptive immune surveillance. *Nat Commun.* 2017;8:1-15. doi:10.1038/ncomms14760
15. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. *Cell Host Microbe*. 2020;27:671-680.e2.

16. Tanno H, Gould TM, McDaniel JR, et al. Determinants governing T cell receptor α/β-chain pairing in repertoire formation of identical twins. *Proc Natl Acad Sci USA*. 2020;117:532-540.

17. Reed E, Hedström AK, Hansson M, et al. Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity. *Arthritis Res Ther*. 2020;22:170.

18. Kaminski H, Garrigue I, Couzi L, et al. Surveillance of γδ T cells predicts cytomegalovirus infection resolution in kidney transplants. *J Am Soc Nephrol*. 2016. doi:10.1681/ASN.2014100985

19. Carissimo G, Xu W, Kwok J, et al. Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. *Nat Commun*. 2020;11:1-12. doi:10.1038/s41467-020-19080-6

20. Jani M, Barton A, Hyrich K. Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification? *Curr Opin Rheumatol*. 2019;31:285-292.

21. Bower H, Frisell T, Di Giuseppe D, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. *Ann Rheum Dis*. 2021;80:1086-1093.

22. Serling-Boyd N, D'Silva KM, Hsu TY, et al. Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. *Ann Rheum Dis*. 2021;80:660-666.

23. Picchianti-Diamanti A, Aiello A, Laganà B, et al. Immunosuppressive Therapies Differently Modulate Humoral-and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. *Front Immunol*. 2021. doi:10.3389/fimmu.2021.740249

24. Zvyagin IV, Pogorelyy MV, Ivanova ME, et al. Distinctive properties of identical twins’ TCR repertoires revealed by high-throughput sequencing. *Proc Natl Acad Sci USA*. 2014;111:5980-5985.

25. Goletti D, Petrone L, Manissero D, et al. The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. *Clin Microbiol Infect*. 2021;27:1784-1789.

26. Arruda L, Gaballa A, Rodrigues R, Makower B, Uhlin M. 2022; immuneACCESS. doi:10.21417/LCMA2022SJI

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.